Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback